ArticleCancer medicine2023

Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.

Dae Ho Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.